Ocugen, Inc. Share Price
NASDAQ: OCGN | Small CapOcugen, Inc. Stock Performance
Open $1.38 | Prev. Close $1.36 | Circuit Range N/A |
Day Range $1.38 - $1.42 | Year Range $0.98 - $2.72 | Volume 1,37,791 |
Average Traded $1.39 |
Ocugen, Inc. Share Price Today
As of 14 August 2026, Ocugen, Inc.'s share price is $1.41. The stock opened at $1.38, compared to its previous close of $1.36. During today's trading session, Ocugen, Inc.'s share price traded between $1.38 and $1.42, with an average price of $1.40. Over the past 52 weeks, the stock has recorded a high of $2.72 and a low of $0.98. In terms of performance, Ocugen, Inc.'s share price has declined by 22.80% over the last six months and is up 38.56% on a year-on-year basis.
Ocugen, Inc. Share Price Chart
Ocugen, Inc. Stock Fundamentals & Key Indicators
Market Cap $421.74M | PE Ratio (TTM) -6.11 | Dividend Yield N/A |
EPS (TTM) $-0.23 | Revenue (TTM) $4.41M | Return On Equity (TTM) 557.67% |
Profit Margin -1537.41% | Debt to Equity -1.89 | Quarterly Earnings Growth YoY N/A |
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.25 | $1.41 | +12.40% |
Jul 2026 | $1.54 | $1.25 | -18.83% |
Jun 2026 | $1.37 | $1.54 | +11.59% |
May 2026 | $1.73 | $1.38 | -20.46% |
Apr 2026 | $1.84 | $1.74 | -4.41% |
Mar 2026 | $1.67 | $1.81 | -0.27% |
Feb 2026 | $1.45 | $1.82 | +25.09% |
Jan 2026 | $1.36 | $1.46 | +8.58% |
Dec 2025 | $1.25 | $1.34 | +8.06% |
Nov 2025 | $1.58 | $1.24 | -20.00% |
Oct 2025 | $1.64 | $1.55 | -4.91% |
Sep 2025 | $1.02 | $1.63 | +60.75% |
OCGN Share Price FAQs
What is Ocugen, Inc. share price today?
What is the 52 week high and 52 week low of Ocugen, Inc. stock?
What is OCGN's market capitalisation today?
What is the 5 year returns of OCGN?
What is the high & low stock price of OCGN today?
Can I buy OCGN shares in India?